In a phase II study of the anti-PD1 agent pembrolizumab, patients have improved PFS rates at 6 months, compared to historical controls, and a non-significant association between increased PD-L1 expression and reduced tumor growth (113). The gene discussed is CD274; the disease is neoplasm.